Merck & Co., Inc. (NYSE:MRK) Shares Sold by Accurate Wealth Management LLC

Accurate Wealth Management LLC lowered its stake in Merck & Co., Inc. (NYSE:MRKFree Report) by 13.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 12,386 shares of the company’s stock after selling 1,886 shares during the period. Accurate Wealth Management LLC’s holdings in Merck & Co., Inc. were worth $1,467,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. Cantor Fitzgerald Investment Advisor L.P grew its stake in shares of Merck & Co., Inc. by 94.2% during the first quarter. Cantor Fitzgerald Investment Advisor L.P now owns 349,588 shares of the company’s stock worth $28,683,000 after purchasing an additional 169,536 shares in the last quarter. BCK Partners Inc. purchased a new stake in Merck & Co., Inc. during the first quarter worth approximately $2,423,000. NewEdge Advisors LLC boosted its holdings in Merck & Co., Inc. by 6.3% in the first quarter. NewEdge Advisors LLC now owns 159,225 shares of the company’s stock valued at $13,064,000 after purchasing an additional 9,376 shares in the last quarter. First Western Trust Bank purchased a new position in Merck & Co., Inc. in the first quarter valued at approximately $1,078,000. Finally, Equitable Holdings Inc. raised its holdings in Merck & Co., Inc. by 12.9% during the first quarter. Equitable Holdings Inc. now owns 36,124 shares of the company’s stock worth $2,964,000 after purchasing an additional 4,131 shares in the last quarter. Hedge funds and other institutional investors own 74.59% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $123.85 on Friday. The firm has a market capitalization of $313.67 billion, a PE ratio of 884.71, a P/E/G ratio of 0.49 and a beta of 0.37. The stock’s 50 day moving average is $123.83 and its two-hundred day moving average is $111.98. Merck & Co., Inc. has a twelve month low of $99.14 and a twelve month high of $130.24. The company has a current ratio of 1.25, a quick ratio of 1.00 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last issued its earnings results on Thursday, February 1st. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.12. Merck & Co., Inc. had a net margin of 0.61% and a return on equity of 9.33%. The company had revenue of $14.63 billion for the quarter, compared to analyst estimates of $14.49 billion. During the same period in the prior year, the business posted $1.62 earnings per share. The firm’s revenue for the quarter was up 5.8% compared to the same quarter last year. Research analysts anticipate that Merck & Co., Inc. will post 8.58 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Investors of record on Friday, March 15th will be given a $0.77 dividend. The ex-dividend date is Thursday, March 14th. This represents a $3.08 annualized dividend and a dividend yield of 2.49%. Merck & Co., Inc.’s dividend payout ratio is presently 2,200.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Steven Mizell sold 50,694 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now directly owns 23,619 shares in the company, valued at $2,991,346.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of the stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total transaction of $124,890.00. Following the transaction, the insider now owns 19,569 shares of the company’s stock, valued at approximately $2,443,972.41. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Steven Mizell sold 50,694 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the transaction, the executive vice president now owns 23,619 shares in the company, valued at $2,991,346.35. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

MRK has been the subject of several research analyst reports. Societe Generale cut shares of Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a report on Monday, March 11th. Barclays lifted their target price on Merck & Co., Inc. from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, February 2nd. TD Cowen raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $125.00 to $135.00 in a research report on Thursday, January 4th. Wells Fargo & Company raised their target price on shares of Merck & Co., Inc. from $125.00 to $130.00 and gave the stock an “equal weight” rating in a research report on Friday, February 2nd. Finally, UBS Group upped their price target on shares of Merck & Co., Inc. from $135.00 to $148.00 and gave the company a “buy” rating in a research report on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $129.14.

View Our Latest Stock Report on Merck & Co., Inc.

About Merck & Co., Inc.

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.